KORU Medical Systems Celebrates Record Revenues for 2024

KORU Medical Systems Reports Outstanding Performance in 2024

KORU Medical Systems (NASDAQ: KRMD) has recently shared impressive preliminary results for their fourth quarter and full year of 2024. As a prominent player in the medical technology field, the company focuses on innovative solutions for large volume subcutaneous infusion. With a remarkable net revenue of approximately $8.9 million for the fourth quarter alone, KORU Medical has experienced significant growth of 23% compared to the same period last year.

Strong Annual Growth and Cash Flow Highlights

For the complete year, KORU Medical forecasts net revenues reaching around $33.7 million, marking a substantial increase of 18% year-over-year. This outstanding performance also includes a notable cash balance of $9.6 million, representing a positive cash flow of $0.8 million in the fourth quarter. These results demonstrate a remarkable 67% improvement in cash burn from the prior year, showcasing the company's careful management and strategic execution.

Corporate Strategy and Market Development

Linda Tharby, President and CEO of KORU Medical, expressed her pride in the company’s achievements, commenting, "We executed on all aspects of our strategic plan as we continued to win share in the US market and expanded our international footprint. This progress is accompanied by efforts to add new drug therapies to our label, which positions us favorably for future growth. Our improved margins and disciplined cash use further enhance our readiness for upcoming opportunities."

Commitment to Patient-Centric Solutions

KORU Medical’s dedication to enhancing patient experiences is evident in their innovative solutions. The FREEDOM Syringe Infusion System, which has been delivering exceptional results since its FDA clearance in 1994, enables patients to self-administer therapy in a comfortable home environment or receive care in an ambulatory infusion center. This flexibility is key in improving patients' quality of life throughout their treatment journeys.

Upcoming Financial Announcements

The company plans to fully disclose its fourth quarter and annual financial results in early March 2025. While preliminary figures are very promising, they remain subject to adjustments after the review by independent auditors.

Expansion Through Novel Therapies

KORU Medical’s Novel Therapies division plays a crucial role in tailoring solutions for biopharmaceutical companies. During clinical trials, KORU Medical provides essential products and adapts the Freedom System according to the unique needs of various drug categories. This approach solidifies their position as a vital partner in the drug development process.

Looking Ahead

As KORU Medical moves into 2025, the company is enthusiastic about leveraging its strong momentum. With continued support from ongoing growth strategies and market expansion, KORU aims to solidify its status as a global leader in drug delivery systems.

Frequently Asked Questions

What were KORU Medical's revenue results for 2024?

KORU Medical reported preliminary revenues of $33.7 million for 2024, indicating an 18% growth over the previous year.

How much cash flow did KORU Medical achieve in Q4 2024?

The company experienced positive cash flow of $0.8 million for the fourth quarter of 2024.

What is the FREEDOM Syringe Infusion System?

The FREEDOM Syringe Infusion System is an innovative solution for large volume subcutaneous infusion, enabling self-administration by patients or professional care in ambulatory infusion centers.

When will KORU Medical release its full financial results?

KORU Medical plans to release its comprehensive fourth quarter and annual financial results in early March 2025.

How does KORU Medical support drug development?

Through its Novel Therapies division, KORU Medical supplies products for clinical trials, customizing solutions for different drug categories as needed.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.